Triumvira Immunologics Inc., an Austin, Texas-based biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, completed a USD $55m Series A financing round.
The round was co-led by Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures. Additional investors include Oceanpine Capital and Viva Biotech Holdings, and existing investors include Bloom Burton & Co. and the Centre for Commercialization of Cancer Immunotherapy (C3i).
This financing will enable Triumvira to advance multiple autologous and allogeneic programs into the clinic for solid tumors and hematologic malignancies.
Led by Dr. Paul Lammers, President and CEO, Triumvira is committed to develop novel T-cell therapies as cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T-cell receptor (TCR) therapies.
The company’s foundational technology is the T-cell Antigen Coupler (TAC). TAC is a hybrid molecule comprising multiple protein domains to combine tumor targeting abilities with the T-cell’s own activation machinery, leveraging the potential for the development of superior therapies for a broad range of patients with solid or liquid malignancies.
Its preclinical data with autologous and allogeneic programs demonstrate unique biological differences between TAC-engineered T-cells and second-generation CAR-T cells, with TAC-T cells showing absence of tonic signaling, strong tumor penetration, and long-term persistence. These functional properties help TAC T-cells produce strong anti-tumor activity and no evidence of toxicity, particularly in models of solid tumors.
Dr. Juergen Eckhardt and Dr. Jak Knowles will represent Leaps by Bayer by actively participating on Triumvira’s board of directors together with Dr. Shaan Gandhi, Principal at Northpond Ventures. Additionally, Scott Smith, current President at BioAtla and former President and Chief Operating Officer at Celgene, has been named Chairman of the Board. Brian Bloom, Dr. Paul Lammers, Dr. John Holyoake, and independent Director Cynthia Collins, President & CEO at Editas Medicine, will remain on the Triumvira board.
The company also has research facilities in Hamilton, Ontario.